FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280492688> ?p ?o ?g. }

• W4280492688 endingPage "253" @default.
• W4280492688 startingPage "243" @default.
• W4280492688 abstract "Despite established efficacy, there is low engagement in prolonged exposure (PE) therapy for PTSD among combat veterans. In preparation for a full-scale randomized trial, we sought to evaluate the feasibility, safety, and preliminary efficacy of quetiapine to enhance patient engagement in PE therapy. Open-label, randomized pilot trial of quetiapine monotherapy vs. Treatment as Usual (TAU) medications in 20 military veterans with combat related PTSD who were seeking care from the San Antonio Polytrauma Rehabilitation Center at the South Texas Veterans Healthcare System (STVHCS). Participants were randomized to receive either Quetiapine ( n = 10) monotherapy or pharmacological TAU ( n = 10) in patients who were receiving PE as a standard of care therapy. We collected information on (1) the number of potentially eligible veterans approached, the number screened, and the number randomized, (2) adverse events reported, (3) number of participants continuing PE treatment at least until session #4 (i.e., after first exposure session) and the total number of sessions of PE completed by the participants, and (4) change in PTSD severity and sleep quality measured by the PTSD Checklist for DSM-5 (PCL-5) and Pittsburgh Sleep Quality Index (PSQI). Data were analyzed for 18 intent-to-treat participants with mean (SD) age, 53.5 (13.4) years; and baseline PCL-5 score, 57.6 (7.6). More veterans in the quetiapine group ( n = 9; 100%) received at least the first exposure session of PE therapy compared to TAU (( n = 3; (37.5%), p = .006] and completed PE therapy ( n = 8; (88.9%) vs ( n = 3; (37.5%), p = .03). Both PCL-5 ( p = .03) and PSQI ( p = .02) scores decreased significantly more for participants in the quetiapine than the TAU group. Preliminary findings support the feasibility, safety, and possible efficacy of quetiapine as an adjunct to enhancing engagement in PE therapy. A full-scale randomized trial is required to determine the true efficacy of quetiapine to enhance engagement in PE treatment." @default.
• W4280492688 created "2022-05-22" @default.
• W4280492688 creator A5021215415 @default.
• W4280492688 creator A5022717200 @default.
• W4280492688 creator A5025828684 @default.
• W4280492688 creator A5038790916 @default.
• W4280492688 creator A5044148053 @default.
• W4280492688 creator A5045510234 @default.
• W4280492688 creator A5065995488 @default.
• W4280492688 creator A5070930467 @default.
• W4280492688 creator A5079162364 @default.
• W4280492688 creator A5087404856 @default.
• W4280492688 creator A5087899369 @default.
• W4280492688 date "2022-11-01" @default.
• W4280492688 modified "2023-09-30" @default.
• W4280492688 title "Quetiapine as an adjunct to enhance engagement in prolonged exposure therapy for PTSD in veterans: A randomized, pilot trial" @default.
• W4280492688 cites W127048576 @default.
• W4280492688 cites W1821730900 @default.
• W4280492688 cites W1897337326 @default.
• W4280492688 cites W1956764134 @default.
• W4280492688 cites W1963729682 @default.
• W4280492688 cites W1975615075 @default.
• W4280492688 cites W1983377547 @default.
• W4280492688 cites W1985674713 @default.
• W4280492688 cites W2005290930 @default.
• W4280492688 cites W2011761770 @default.
• W4280492688 cites W2023216463 @default.
• W4280492688 cites W2027757754 @default.
• W4280492688 cites W2030199017 @default.
• W4280492688 cites W2056245842 @default.
• W4280492688 cites W2061214350 @default.
• W4280492688 cites W2068975922 @default.
• W4280492688 cites W2069988391 @default.
• W4280492688 cites W2078154303 @default.
• W4280492688 cites W2083918056 @default.
• W4280492688 cites W2086058909 @default.
• W4280492688 cites W2093274439 @default.
• W4280492688 cites W2136341379 @default.
• W4280492688 cites W2160848506 @default.
• W4280492688 cites W2168434488 @default.
• W4280492688 cites W2170684975 @default.
• W4280492688 cites W2194017231 @default.
• W4280492688 cites W2468169686 @default.
• W4280492688 cites W2519805123 @default.
• W4280492688 cites W2581848244 @default.
• W4280492688 cites W2598895258 @default.
• W4280492688 cites W2779008721 @default.
• W4280492688 cites W2787126648 @default.
• W4280492688 cites W2898977022 @default.
• W4280492688 cites W2943544081 @default.
• W4280492688 cites W2944434778 @default.
• W4280492688 cites W2969385726 @default.
• W4280492688 cites W2996581066 @default.
• W4280492688 cites W3177583487 @default.
• W4280492688 doi "https://doi.org/10.1016/j.jbct.2022.04.001" @default.
• W4280492688 hasPublicationYear "2022" @default.
• W4280492688 type Work @default.
• W4280492688 citedByCount "1" @default.
• W4280492688 countsByYear W42804926882022 @default.
• W4280492688 crossrefType "journal-article" @default.
• W4280492688 hasAuthorship W4280492688A5021215415 @default.
• W4280492688 hasAuthorship W4280492688A5022717200 @default.
• W4280492688 hasAuthorship W4280492688A5025828684 @default.
• W4280492688 hasAuthorship W4280492688A5038790916 @default.
• W4280492688 hasAuthorship W4280492688A5044148053 @default.
• W4280492688 hasAuthorship W4280492688A5045510234 @default.
• W4280492688 hasAuthorship W4280492688A5065995488 @default.
• W4280492688 hasAuthorship W4280492688A5070930467 @default.
• W4280492688 hasAuthorship W4280492688A5079162364 @default.
• W4280492688 hasAuthorship W4280492688A5087404856 @default.
• W4280492688 hasAuthorship W4280492688A5087899369 @default.
• W4280492688 hasConcept C118552586 @default.
• W4280492688 hasConcept C126322002 @default.
• W4280492688 hasConcept C138885662 @default.
• W4280492688 hasConcept C15744967 @default.
• W4280492688 hasConcept C168563851 @default.
• W4280492688 hasConcept C2776412080 @default.
• W4280492688 hasConcept C2777056012 @default.
• W4280492688 hasConcept C2778251122 @default.
• W4280492688 hasConcept C2780634440 @default.
• W4280492688 hasConcept C2994577977 @default.
• W4280492688 hasConcept C41895202 @default.
• W4280492688 hasConcept C558461103 @default.
• W4280492688 hasConcept C71924100 @default.
• W4280492688 hasConceptScore W4280492688C118552586 @default.
• W4280492688 hasConceptScore W4280492688C126322002 @default.
• W4280492688 hasConceptScore W4280492688C138885662 @default.
• W4280492688 hasConceptScore W4280492688C15744967 @default.
• W4280492688 hasConceptScore W4280492688C168563851 @default.
• W4280492688 hasConceptScore W4280492688C2776412080 @default.
• W4280492688 hasConceptScore W4280492688C2777056012 @default.
• W4280492688 hasConceptScore W4280492688C2778251122 @default.
• W4280492688 hasConceptScore W4280492688C2780634440 @default.
• W4280492688 hasConceptScore W4280492688C2994577977 @default.
• W4280492688 hasConceptScore W4280492688C41895202 @default.
• W4280492688 hasConceptScore W4280492688C558461103 @default.
• W4280492688 hasConceptScore W4280492688C71924100 @default.
• W4280492688 hasIssue "4" @default.

• next